The company said, “The Company continues to anticipate net product revenue of between $480 million and $495 million for the full year 2026.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics submits Zoryve supplemental new drug application
- Arcutis Biotherapeutics: Near-Term Cost Pressures but Intact Long-Term Growth Thesis Supports Buy Rating
- Arcutis Biotherapeutics presents new Phase 2 results on Zoryve cream
- Arcutis Biotherapeutics to present clinical data on ZORYVE at AAD Meeting
- Arcutis Biotherapeutics announces publication on Phase 3 study of Zoryve cream